Literature DB >> 16596280

CD4+ T cells and the Th1/Th2 imbalance are implicated in the pathogenesis of Graves' ophthalmopathy.

Ning Xia1, Suxian Zhou, Yuzhen Liang, Changqing Xiao, Hanlei Shen, Hailin Pan, Hongming Deng, Naizun Wang, Qingdi Q Li.   

Abstract

Graves' ophthalmopathy (GO) is considered to be an organ-specific autoimmune disease. However, the pathogenesis of GO is incompletely understood at the present time. To clarify the immunological differences between newly diagnosed GO and Graves' disease (GD) without ophthalmopathy or healthy controls (HC), we examined T-cell profile and the Th1/Th2 profile cell balance in GO (n=20), GD (n=20) and HC (n=20) using flow cytometry. We also assessed the influence of methimazole on the immunocyte profiles in patients with GO and GD and analyzed the relationship of the immunologic changes with CAS, FT3, FT4, TRAb, TMA and TGA among the three investigated groups. We report in this study that: 1) The percentage of CD4+ T cells and the ratio of CD4+/CD8+ cells were higher, but the population of CD8+ T cells was lower in both GO and GD than those of HC (P<0.05); 2) The percentage of CD8-/IFNgamma+ T cells (Th1) and the ratio of CD8-/IFNgamma+ to CD8-/IL-4+ T cells (Th1/Th2) in GO were considerably higher as compared to those in GD and HC (P<0.05). On the contrary, the population of Th1 cells, as well as the ratio of Th1/Th2 cells, was lower in GD than that of GO and HC (P<0.05); 3) There were no significant differences in T-cell profile and the Th1/Th2 cell balance in either GO or GD patients before and after methimazole treatment; 4) There was a positive correlation of Th1 cell percentage and the Th1/Th2 cell ratio with the clinical activity score (CAS) in GO (P<0.05), whereas CAS in GO had no correlation with the T-cell profile, the percentage of Th2 cells, and TRAb (P>0.05); 5) T-cell subset and the ratio of Th1/Th2 cells did not correlate significantly with FT3, FT4, TRAb, TMA, or TGA in GO and GD (P>0.05). Finally, 6) there were no statistical differences in TRAb, TMA, and TGA between early GO and GD without ophthalmopathy (P>0.05). Collectively, these results indicate that the balance of Th1/Th2 in GO shifts to Th1 dominance and that the cellular immune responses mediated by the Th1-type CD4+ cells might play a dominant role in the pathogenesis of GO, and thus suggest that the Th1 cell percentage and the ratio of Th1/Th2 cell subsets may be potentially utilized as clinical parameters for disease activity, for monitoring the effectiveness of immunosuppressive treatment, or for developing immunospecific forms of therapy for Graves' ophthalmopathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16596280

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  23 in total

Review 1.  Cytokines, Graves' disease, and thyroid-associated ophthalmopathy.

Authors:  Andrew G Gianoukakis; Nicole Khadavi; Terry J Smith
Journal:  Thyroid       Date:  2008-09       Impact factor: 6.568

2.  beta-2-adrenergic receptor gene polymorphism confers susceptibility to Graves disease.

Authors:  Krystian Jazdzewski; Tomasz Bednarczuk; Magdalena Stepnowska; Sandya Liyanarachchi; Krystyna Suchecka-Rachon; Janusz Limon; Krzysztof Narkiewicz
Journal:  Int J Mol Med       Date:  2007-01       Impact factor: 4.101

3.  The peripheral blood compartment in patients with Graves' disease: activated T lymphocytes and increased transitional and pre-naive mature B lymphocytes.

Authors:  K Van der Weerd; P M Van Hagen; B Schrijver; D J Kwekkeboom; W W De Herder; M R J Ten Broek; P T E Postema; J J M Van Dongen; F J T Staal; W A Dik
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

4.  MicroRNA-146a contributes to CD4+ T lymphocyte differentiation in patients with thyroid ophthalmopathy.

Authors:  Wen-Juan Yang; Peng-Fei Ma; Shu-Ping Li; Hong Su; Yun-Jia Liu
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

5.  Cytokine production in thyroid eye disease: in vitro effects of dexamethasone and IL-6 blockade with tocilizumab.

Authors:  Anna Leszczynska; Blanca Molins; Estrella Fernández; Alfredo Adán; Santiago Ortiz-Perez
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-07-23       Impact factor: 3.117

Review 6.  Selenium: an element for life.

Authors:  Leonidas H Duntas; Salvatore Benvenga
Journal:  Endocrine       Date:  2014-12-18       Impact factor: 3.633

7.  RhoA with Associated TRAb or FT3 in the Diagnosis and Prediction of Graves' Ophthalmopathy.

Authors:  Sidi Zhao; Shuangshuang Shi; Wanchen Yang; Hanqing Wang; Tianming Jian; Qing He; Yang Liu; Xiaoming Huang; Tong Wu
Journal:  Dis Markers       Date:  2022-07-29       Impact factor: 3.464

8.  PD-L1 Inhibits T Cell-Induced Cytokines and Hyaluronan Expression via the CD40-CD40L Pathway in Orbital Fibroblasts From Patients With Thyroid Associated Ophthalmopathy.

Authors:  Zhibin Liu; Yao Liu; Mingming Liu; Qingjia Gong; Anjie Shi; Xiuhong Li; Xu Bai; Xiaoyue Guan; Bing Hao; Feila Liu; Xing Zhou; Hongfeng Yuan
Journal:  Front Immunol       Date:  2022-05-10       Impact factor: 8.786

9.  The evolving role of selenium in the treatment of graves' disease and ophthalmopathy.

Authors:  Leonidas H Duntas
Journal:  J Thyroid Res       Date:  2012-01-19

10.  CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis.

Authors:  Michael P Pender
Journal:  Autoimmune Dis       Date:  2012-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.